201 related articles for article (PubMed ID: 31810095)
1. Impact of Viral Etiologies on the Development of Novel Immunotherapy for Hepatocellular Carcinoma.
Lim CJ; Chew V
Semin Liver Dis; 2020 May; 40(2):131-142. PubMed ID: 31810095
[TBL] [Abstract][Full Text] [Related]
2. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
Front Immunol; 2020; 11():1037. PubMed ID: 32547550
[TBL] [Abstract][Full Text] [Related]
3. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
Marotta F; Vangieri B; Cecere A; Gattoni A
Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.
Keenan BP; Fong L; Kelley RK
J Immunother Cancer; 2019 Oct; 7(1):267. PubMed ID: 31627733
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of Hepatocellular Carcinoma.
Heinrich B; Czauderna C; Marquardt JU
Oncol Res Treat; 2018; 41(5):292-297. PubMed ID: 29705790
[TBL] [Abstract][Full Text] [Related]
6. Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers.
Tai D; Choo SP; Chew V
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31816940
[TBL] [Abstract][Full Text] [Related]
7. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
Ding Z; Dong Z; Chen Z; Hong J; Yan L; Li H; Yao S; Yan Y; Yang Y; Yang C; Li T
Front Immunol; 2021; 12():733530. PubMed ID: 34659220
[TBL] [Abstract][Full Text] [Related]
8. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
9. The Promise of Immunotherapy in the Treatment of Hepatocellular Carcinoma.
El-Khoueiry A
Am Soc Clin Oncol Educ Book; 2017; 37():311-317. PubMed ID: 28561676
[TBL] [Abstract][Full Text] [Related]
10. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
11. Prospects and Challenges for T Cell-Based Therapies of HCC.
Woller N; Engelskircher SA; Wirth T; Wedemeyer H
Cells; 2021 Jun; 10(7):. PubMed ID: 34209393
[TBL] [Abstract][Full Text] [Related]
12. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
[TBL] [Abstract][Full Text] [Related]
13. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma.
Montella L; Sarno F; Ambrosino A; Facchini S; D'Antò M; Laterza MM; Fasano M; Quarata E; Ranucci RAN; Altucci L; Berretta M; Facchini G
Cells; 2021 Jul; 10(8):. PubMed ID: 34440678
[TBL] [Abstract][Full Text] [Related]
14. Immune landscape and immunotherapy of hepatocellular carcinoma: focus on innate and adaptive immune cells.
Gao X; Zuo S
Clin Exp Med; 2023 Oct; 23(6):1881-1899. PubMed ID: 36773210
[TBL] [Abstract][Full Text] [Related]
15. Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy.
Zhong K; Xu Y; Cheng Y; Wen Y; Cai L; He G; Huang H; Fu S; Zhong X; Zheng Y; Chen T; Huang M; Pan M
Front Immunol; 2022; 13():999763. PubMed ID: 36119069
[TBL] [Abstract][Full Text] [Related]
16. Challenges in cancer vaccine development for hepatocellular carcinoma.
Buonaguro L; Petrizzo A; Tagliamonte M; Tornesello ML; Buonaguro FM
J Hepatol; 2013 Oct; 59(4):897-903. PubMed ID: 23714157
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?
Obeid JM; Kunk PR; Zaydfudim VM; Bullock TN; Slingluff CL; Rahma OE
Cancer Immunol Immunother; 2018 Feb; 67(2):161-174. PubMed ID: 29052780
[TBL] [Abstract][Full Text] [Related]
18. Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.
Hsu PY; Hsu CT; Yeh ML; Huang CF; Huang CI; Liang PC; Lin YH; Hsieh MY; Wei YJ; Hsieh MH; Dai CY; Lin ZY; Chen SC; Huang JF; Yu ML; Chuang WL
Dig Dis Sci; 2020 Jul; 65(7):2120-2129. PubMed ID: 31722058
[TBL] [Abstract][Full Text] [Related]
19. Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment.
Stella L; Santopaolo F; Gasbarrini A; Pompili M; Ponziani FR
World J Gastroenterol; 2022 Jun; 28(21):2251-2281. PubMed ID: 35800182
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma in viral and autoimmune liver diseases: Role of CD4+ CD25+ Foxp3+ regulatory T cells in the immune microenvironment.
Granito A; Muratori L; Lalanne C; Quarneti C; Ferri S; Guidi M; Lenzi M; Muratori P
World J Gastroenterol; 2021 Jun; 27(22):2994-3009. PubMed ID: 34168403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]